Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022

Rhea-AI Summary

Kamada Ltd. (NASDAQ: KMDA) will release its Q2 and first-half financial results on August 17, 2022, before U.S. market open. An investment community conference call will follow at 8:30 AM ET, with participation options provided. The company focuses on specialty plasma-derived therapeutics, boasting a diverse portfolio including FDA-approved products such as GLASSIA® and KEDRAB®. Kamada also has a robust development pipeline, particularly in inhaled AAT therapy for AAT deficiency, currently in a pivotal Phase 3 trial.

Positive

• Diverse portfolio of FDA-approved plasma-derived products including GLASSIA® and KEDRAB®.
• Strong development pipeline with ongoing InnovAATe clinical trial for inhaled AAT therapy.
• Strategic presence in over 30 countries, enhancing market reach.

Negative

• None.

REHOVOT, Israel and HOBOKEN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the second quarter and first half ended June 30, 2022, prior to the open of the U.S. financial markets on Wednesday, August 17, 2022.

Kamada management will host an investment community conference call on Wednesday, August 17, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel), or 1 201-689-8263 (International) and entering the conference identification number: 13732049. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1562507&tp_key=0cee4cf215.

The call will also be archived for 90 days on the Company’s website at www.kamada.com.

About Kamada
Kamada Ltd. (the “Company”) is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will Kamada release its financial results for Q2 2022?

Kamada will release its Q2 financial results on August 17, 2022.

What time is Kamada's investment community conference call?

The conference call will be held at 8:30 AM ET on August 17, 2022.

What products are included in Kamada's commercial portfolio?

Kamada's commercial portfolio includes FDA-approved products like GLASSIA® and KEDRAB®.

What is the focus of Kamada's clinical development pipeline?

Kamada's pipeline focuses on specialty plasma-derived therapeutics, including inhaled AAT for AAT deficiency.